| Retatrutide | Tirzepatide | |
|---|---|---|
| Targets | GLP-1 + GIP + glucagon (triple) | GLP-1 + GIP (dual) |
| Brand names | None — investigational | Mounjaro®, Zepbound® |
| FDA status (2026) | Phase 3 trials, not approved | Approved for type 2 diabetes & obesity |
| Weekly doses studied | 2–12 mg | 2.5–15 mg |
| Reported weight loss | Up to ~24% in Phase 2 | Up to ~21% (SURMOUNT-1) |
| How to get it | Clinical trial only | Prescription via licensed provider |
The headline difference is the third receptor. By adding glucagon-receptor activity, retatrutide may increase energy expenditure on top of the appetite effects shared with tirzepatide — which could explain the larger weight loss seen in early studies. The trade-off is maturity: tirzepatide is FDA-approved and widely used, while retatrutide is still being tested.
If you want results today, tirzepatide is an approved, prescribable option. Use the tirzepatide calculator to reconstitute compounded product, or the dosage chart for the standard titration.
Get tirzepatide with a licensed provider
A prescription matters: real reconstitution should be done with pharmacy-grade product and clinician guidance. These telehealth services handle the evaluation, prescription, and shipping.
Ro — weight loss program →Henry Meds →Frequently asked questions
Is retatrutide better than tirzepatide?
Can you switch from tirzepatide to retatrutide?
Dose with confidence — free tips by email
Practical dosing guides, reconstitution tips, and ways to save on your meds — about once a week, no fluff.